Xaliproden
From Wikipedia, the free encyclopedia
 |
|
|
Xaliproden
|
|
| Systematic (IUPAC) name | |
| 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine | |
| Identifiers | |
| CAS number | |
| ATC code | N07 |
| PubChem | |
| Chemical data | |
| Formula | C24H22F3N |
| Mol. mass | 381.433 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Xaliproden is a drug which has been proposed for use in the treatment of Alzheimer's disease.[1]
Development of xaliproden for Alzheimer's disease was discontinued in 2007 following analysis of phase III data. While the drug did not show efficacy in cognitive decline, there was an effect on hippocampal volume (suggesting perhaps a slowing of cell loss). Xaliproden remains under investigation for treatment of peripheral neuropathy associated with chemotherapy.
[edit] References
- ^ Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). "Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats.". Invest Radiol 37 (6): 321–7. doi:. PMID 12021588.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
